Literature DB >> 17174632

Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.

Sumit R Majumdar1, Ross T Tsuyuki, Finlay A McAlister.   

Abstract

BACKGROUND: Local opinion leaders are educationally and socially influential physicians. Although they can accelerate the adoption of new evidence in hospitals, their impact on the quality of prescribing for outpatients has only been examined by a few studies. We hypothesized that an intervention consisting of patient-specific one-page evidence summaries, generated and endorsed by local opinion leaders, would improve prescribing of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in heart failure (HF) and that of statins in ischemic heart disease (IHD).
METHODS: We conducted a community-based randomized controlled trial in patients with HF (not receiving ACE inhibitors or ARBs) and those with IHD (not receiving statins) who were recruited from 40 pharmacies and allocated either to the opinion leader intervention or to usual care based on randomization of their primary care physician. The primary outcome was an increase in the use of efficacious therapies (ACE inhibitors or ARBs in HF and statins in IHD) within 6 months; the secondary outcomes were prescribing changes for HF or IHD.
RESULTS: A total of 171 patients participated in the study; 87 were allocated to the intervention, whereas 84 were assigned to the control group. The median age of the participants was 75 years; 103 (60%) were female, 54 (32%) had HF, and 117 (68%) had IHD. Overall, 21 (24%) intervention patients started receiving an efficacious medication within 6 months, as compared with 15 (18%) control subjects (relative risk of improvement 1.32, 95% CI 0.73-2.40, P = .31). In the HF subgroup, 38% of the intervention patients started receiving an ACE inhibitor or ARB therapy, as compared with 20% of control subjects (relative risk of improvement 1.90, 95% CI 0.76-4.72, P = .15). In the IHD subgroup, 17% of the intervention patients and 17% of the control subjects started receiving statin therapy (P = .97).
CONCLUSIONS: The influence of local opinion leaders may be useful for improving the quality of cardiovascular prescribing in the community, but the benefits are likely modest and may be disease specific. Further studies on this method are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17174632     DOI: 10.1016/j.ahj.2006.07.030

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  19 in total

Review 1.  Local opinion leaders: effects on professional practice and health care outcomes.

Authors:  Gerd Flodgren; Elena Parmelli; Gaby Doumit; Melina Gattellari; Mary Ann O'Brien; Jeremy Grimshaw; Martin P Eccles
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

2.  The Enhancing Secondary Prevention in Coronary Artery Disease trial.

Authors:  Finlay A McAlister; Miriam Fradette; Sumit R Majumdar; Randall Williams; Michelle Graham; James McMeekin; William A Ghali; Ross T Tsuyuki; Merril L Knudtson; Jeremy Grimshaw
Journal:  CMAJ       Date:  2009-11-23       Impact factor: 8.262

Review 3.  The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs.

Authors:  Jonathan G Howlett; Robert S McKelvie; Jeannine Costigan; Anique Ducharme; Estrellita Estrella-Holder; Justin A Ezekowitz; Nadia Giannetti; Haissam Haddad; George A Heckman; Anthony M Herd; Debra Isaac; Simon Kouz; Kori Leblanc; Peter Liu; Elizabeth Mann; Gordon W Moe; Eileen O'Meara; Miroslav Rajda; Samuel Siu; Paul Stolee; Elizabeth Swiggum; Shelley Zeiroth
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

4.  Case-based training of evidence-based clinical practice in primary care and decreased mortality in patients with coronary heart disease.

Authors:  Anna Kiessling; Moira Lewitt; Peter Henriksson
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

Review 5.  A T-2 translational research perspective on interventions to improve post-fracture osteoporosis care.

Authors:  S R Majumdar
Journal:  Osteoporos Int       Date:  2011-08-17       Impact factor: 4.507

6.  The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788].

Authors:  Finlay A McAlister; Sumit R Majumdar; Rajdeep S Padwal; Miriam Fradette; Ann Thompson; Ross Tsuyuki; Steven A Grover; Naeem Dean; Ashfaq Shuaib
Journal:  Implement Sci       Date:  2010-04-12       Impact factor: 7.327

7.  Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial.

Authors:  Sumit R Majumdar; Jeffrey A Johnson; Finlay A McAlister; Debbie Bellerose; Anthony S Russell; David A Hanley; Don W Morrish; Walter P Maksymowych; Brian H Rowe
Journal:  CMAJ       Date:  2008-02-26       Impact factor: 8.262

8.  A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial.

Authors:  A Cranney; M Lam; L Ruhland; R Brison; M Godwin; M M Harrison; M B Harrison; T Anastassiades; J M Grimshaw; I D Graham
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

9.  Impact of a multifaceted intervention on cholesterol management in primary care practices: guideline adherence for heart health randomized trial.

Authors:  Alain G Bertoni; Denise E Bonds; Haiying Chen; Patricia Hogan; Lenore Crago; Erica Rosenberger; Ann Hiott Barham; C Randall Clinch; David C Goff
Journal:  Arch Intern Med       Date:  2009-04-13

10.  Local opinion leaders: effects on professional practice and healthcare outcomes.

Authors:  Gerd Flodgren; Mary Ann O'Brien; Elena Parmelli; Jeremy M Grimshaw
Journal:  Cochrane Database Syst Rev       Date:  2019-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.